Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, Horbinski C, Huang RY, Lassman AB, Le Rhun E, van den Bent MJ (2020) Glioblastoma in adults: a society for neuro-oncology (SNO) and European society of neuro-oncology (EANO) consensus review on current management and future directions. Neuro Oncol 22(8):1073–1113. https://doi.org/10.1093/neuonc/noaa106

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745. https://doi.org/10.1200/JCO.2008.16.3055

Article  CAS  PubMed  Google Scholar 

Banks PD, Lasocki A, Lau PKH, Sandhu S, McArthur G, Shackleton M (2019) Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: a case series. Health Sci Rep 2:e115. https://doi.org/10.1002/hsr2.115

Article  PubMed  PubMed Central  Google Scholar 

Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Alfred Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS (2010) Corticosteroid use in Pateints with Glioblastoma at First or Second Relapse treated with Bevacizumab in the BRAIN study. Oncologist 15(12):1329–1334

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wick W, Weller M, van den Bent M, Stupp R (2010) Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol 28(12):e188–189. https://doi.org/10.1200/JCO.2009.26

Article  PubMed  Google Scholar 

Raizer JJ, Grimm S, Chamberlain MC, Nicholas MK, Chandler JP, Muro K, Dubner S, Rademaker AW, Renfrow J, Bredel M (2010) A phase 2 trial of single-agent bevacizumab given in an every3-week schedule for patients with recurrent high-grade gliomas. Cancer 116(22):5297–5305. https://doi.org/10.1002/cncr.25462

Article  CAS  PubMed  Google Scholar 

Krukjian C, Kim ES (2012) Risks and benefits with bevacizumab: evidence and clinical implications. Ther Adv Drug Saf 3(2):59–69. https://doi.org/10.1177/2042098611430109

Article  Google Scholar 

Wakai S, Yamakawa K, Manaka S, Takakura K (1982) Spontaneous intracranial hemorrhage caused by brain tumor: its incidence and clinical significance. Neurosurgery 10(4):437444. https://doi.org/10.1227/00006123-198204000-00004

Article  Google Scholar 

Khasraw M, Holodny A, Goldlust SA, DeAngelis LM (2012) Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. Ann Oncol 23(2):458–463

Article  CAS  PubMed  Google Scholar 

Seidel C, Hentschel B, Simon M, Schnell O et al (2013) A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network. J Neurol 260:847–855

Article  CAS  PubMed  Google Scholar 

Auer TA, Renovanz M, Marini F, Brockmann MA, Tanyildizi Y (2017) Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab. J Neurooncol 133:571–579. https://doi.org/10.1007/s11060-017-2467-z

Article  CAS  PubMed  Google Scholar 

Chinot OL, Wick W, Mason W, Henriksson R et al (2014) Bevacizumab plus Radiotherapy-Temozolomide for newly diagnosed Glioblastoma. New Engl J Med 370:709–722. https://doi.org/10.1056/NEJMoa1308345

Article  CAS  PubMed  Google Scholar 

Ajlan A, Thomas P, Albakr A, Nagpal S, Recht L (2017) Optimizing bevacizumab dosing in glioblastoma: less is more. J Neurooncol 135:99–105

Article  CAS  PubMed  Google Scholar 

Melhem JM, Tahir A, Calabrese E, Granovskaya I, Atenafu EG, Sahgal A, Lim-Fat MJ, Perry JR (2023) Dose-dependent efficacy of bevacizumab in recurrent glioblastoma. J Neurooncol 161:633–641

CAS  PubMed  Google Scholar 

Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, Alexandre J, Durand J-P, Treluyer J-M, Knebelamnn B, Goldwasser F (2011) An Observational Study of Bevacizumab-Induced Hypertension as a clinical biomarker of Antitumor Activity. Oncologist 16(9):1325–1332. https://doi.org/10.1634/theoncologist.2010-0002

Article  CAS  PubMed  PubMed Central  Google Scholar 

Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20(5):807–815. https://doi.org/10.1093/annonc/mdn713

Article  CAS  PubMed  Google Scholar 

Dono A, Zhu P, Holmes E, Takayasu T et al (2023) Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma. J Neurooncol 156(2):353–363. https://doi.org/10.1007/s11060-021-03917-1

Article  CAS  Google Scholar 

Goldman DA, Hovinga K, Reiner AS, Esquenazi Y et al (2018) The relationship between repeat resection and overall survival in patients with glioblastoma: a time-dependent analysis. J Neurosurg 129(5):1231–1239. https://doi.org/10.3171/2017.6.JNS17393

Article  PubMed  PubMed Central  Google Scholar 

Ghiaseddin A, Peters KB (2015) Use of Bevacizumab in recurrent glioblastoma. CNS Oncol 4(3):157–169. https://doi.org/10.2217/cns.15.8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wilson MK, Karakasis K, Oza AM (2015) Outcomes and endpoints in trials of cancer treatment: the past, present, and future. Lancet Oncol 16(1):e32–42. https://doi.org/10.1016/S1470-2045(14)70375-4

Article  PubMed  Google Scholar 

Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of competing risk. J Am Stat Assoc 94:496–509. https://doi.org/10.2307/2670170

Article  Google Scholar 

Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR, Jackson EF (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79(5):1487–1495. https://doi.org/10.1016/j.ijrobp.2009.12.061

Article  CAS  PubMed  PubMed Central  Google Scholar 

Von Baumgarten L, Brucker D, Timiceru A, Kienast Y, Grau S, Burgold S, Herms J, Winkler F (2011) Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res 17(19):6192–6205. https://doi.org/10.1158/1078-0432.CCR-10-1868

Article  Google Scholar 

Apte RS, Chen DS, Ferrara N (2019) VEGF in Signaling and Disease: Beyond Discovery and Development. Cell 176(6):1248–1264. https://doi.org/10.1016/j.cell.2019.01.021

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ranpura V, Hapani S, Wu S (2011) Treatment-related mortality with Bevacizumab in Cancer patients: a Meta-analysis. J Am Med Assoc 305(5):487–494. https://doi.org/10.1001/jama.2011.51

Article  CAS  Google Scholar 

Iwama T, Ohkuma A, Miwa Y, Sugimoto S et al (1992) Brain tumors manifesting as intracranial hemorrhage. Neurol Med Chir (Tokyo) 32(3):130–135. https://doi.org/10.2176/nmc.32.130

Article  CAS  PubMed  Google Scholar 

Jospeh DM, O’Neill AH, Chandra RV, Lai LT (2017) Glioblastoma presenting as spontaneous intracranial haemorrhage: case report and review of the literature. J Clin Neurosci 40:1–5. https://doi.org/10.1016/j.jocn.2016.12.046

Article  Google Scholar 

Schrader B, Barth H, Lang EW, Buhl R et al (2000) Spontaneous intracranial Haematomas caused by Neoplasms. Acta Neurochir (Wien) 142:979–985. https://doi.org/10.1007/s007010070052

Article  CAS  PubMed  Google Scholar 

Lorgis V, Maura G, Coppa G, Hassani K, Taillandier L, Chauffert B, Apetoh L, Ladoire S, Ghiringhelli F (2012) Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. J Neurooncol 108:351–358. https://doi.org/10.1007/s11060-011-0748-5

Article  CAS